



Nyhet

Lund 2017-11-17

Portuguese Oncology Institute of Porto seen on Portuguese television, recruiting patients to study, regarding imILT® treatment of advanced pancreatic cancer

Portuguese Oncology Institute of Porto, Portugal, on Portuguese television, recruiting patients to study, regarding imILT treatment of advanced pancreatic cancer. The study is part of CLS Horizon2020 project. [Watch here.](#)
Read more about CLS ongoing clinical studies [here.](#)

Company contact:

Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)

Ph: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®/Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Boston, MA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se